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SUMMARY
Objective: To evaluate the impact of chronic urticaria on quality of life of outpa-
tients through the university questionnaire Dermatology Life Quality Index (DLQI). 
Methods: Survey of the impact on quality of life caused by chronic urticaria, using the 
DLQI questionnaire validated for the Portuguese language. Patients were interviewed 
during visits to a specialized outpatient clinic between May 2009 and May 2010 at a 
Brazilian public service (Botucatu-SP). DLQI scores were analyzed according to the 
following subgroups: age, gender, education, disease duration, and presence of angio-
edema. Results: We interviewed 100 patients with chronic urticaria. There was a female 
predominance (86%), mean age 41.8 years, mean disease duration of 6 years, and an-
gioedema occurrence in 82% of patients. The mean DLQI score was 13.5, character-
ized by serious impact on quality of life, higher than Hansen’s disease, psoriasis, atopic 
eczema, and basal cell carcinoma. The presence of angioedema was associated with 
higher scores: 14.5 x 9.9 (p < 0.01). Female patients reported greater impact on cloth-
ing, while male patients reported treatment interference with work and study (p < 0.05). 
Conclusion: Chronic urticaria seriously compromises the quality of life of patients eval-
uated at a university service in Brazil, particularly of patients with angioedema.
Keywords: Angioedema, urticaria, quality of life, sickness impact profile; quality of life 
index.
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INTRODUCTION
Chronic urticaria (CU) is a complex disease, which is rarely 
fatal, but significantly undermines the patients’ quality of 
life1. It is characterized by erythematous-edematous pap-
ules and plaques, which are pruritic, evanescent, and recur-
rent at irregular intervals. It lasts more than six weeks and is 
not clinically dierent from the acute form. CU may occur 
concomitantly with angioedema in about 40% of patients1-3. 
It is a common clinical condition, which is among the ten 
most common diagnoses in dermatological services1.
The disease prevalence is 0.1% in the general popula-
tion; 0.27-2.1% in familial research; 1-5% in dermatologi-
cal care; and 10% in visits to allergy clinics3-7. It is estimated 
that 12-25% of the population has had at least one episode 
of urticaria in their lifetime5,8, however, epidemiological 
studies of UC are scarce.
The impact of CU clinical symptoms on patients’ qual-
ity of life (QoL) is oen underestimated, with few reports 
in literature. The Dermatology Life Quality Index (DLQI) 
was the first construct for assessing the quality of life spe-
cifically related to dermatology, developed by Finlay and 
Khan in 19949. It consists of 10 questions that estimate the 
inuence of disease with regard to symptoms, daily ac-
tivities, leisure, work, school, personal relationships, and 
treatment. DLQI was translated and validated into Por-
tuguese (Table 1) and has been already applied to several 
skin diseases10-16. 
Perceptions about the impact of disease on patients’ 
lives are supported by cultural aspects, which justify its 
assessment in dierent populations. To date, there are no 
studies of QoL and CU in Latin American populations. 
The authors’ aim was to assess the impact of chronic ur-
ticaria on quality of life of patients treated at a university 
service in the city of Botucatu, Brazil.
METHODS
A survey of the impact on quality of life caused by CU was 
performed using the DLQI questionnaire validated for the 
Portuguese language (Table 1)16.
From May 2009 to May 2010, we selected consecutive 
patients with CU during their visits to the outpatient clinic 
of urticaria, Medical School, Unesp (Botucatu, SP). Pa-
tients were well informed and agreed to participate in the 
study. The project was approved by the local Institutional 
Ethics Committee (protocol nº 3159/09).
Demographic, clinical, and health-related QoL data 
were investigated. DLQI total score was calculated by sum-
ming the score of each of the 10 questions assessed and in-
terpreted as no impairment of quality of life (0-1), mild im- 
pairment (2-5), moderate impairment (6-10), severe 
impairment (11-20), or very severe impairment (21-30)9. 
Categorical data were represented by percentage fre-
quencies; confidence intervals were estimated at 95% 
(95%  CI) and compared by Person’s chi-square test for 
trend and residual analysis of the contingency table. Con-
tinuous data were represented as means and standard 
deviations, and confidence intervals estimated at 95% 
(95% CI) and compared by Student’s t test. Normality was 
assessed by Shapiro-Wilk test and homoscedasticity by 
Levene17,18. 
Questions* Domains
1. How much has your skin been affected during the past week because of itching, 
inflammation, pain, or stinging?
Symptoms and feelings
2. How much embarrassment or other type of limitation was caused by your skin during 
the past week?
3. How has your skin interfered with your activities of going shopping or sight-seeing, at 
home or public places during the past week? Daily activities
4. Over the last week, how much has your skin influenced the clothes you regularly wear?
5. How much has your skin affected any of your social or leisure activities over past week?
Leisure
6. How difficult was it for you to practice sports over the past week?
7. Did your skin prevent you from working or studying over the past week? ** Work and school
8. How much trouble has your skin created with your partner or any of your close friends 
or relatives? Personal relationships
9. How much difficulty has your skin created in your sex life over the past week?
10. How much trouble did your skin treatment create for you over the last week? Treatment
DLQI, Dermatology Life Quality Index; *Admits as answers: 3 (very much), 2 (a lot), 1 (a little), 0 (no or not relevant); **Admits: 3 (very 
much) or 0 (no or not relevant). If not, ask: Has your skin been a problem for you at work or school? If yes: 2 (very much) or 0 
(no or not relevant).
Table 1 – Questions and domains assessed by the DLQI questionnaire, validated for the Portuguese language16
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Subsequently, analysis of total scores and independent 
variables (gender, age, education, disease duration and 
presence of angioedema), according to subgroups, was 
performed. Data were adjusted by analysis of covariance17. 
The result of question scores was assessed by dendro-
gram resulting from hierarchical cluster analysis, and the 
questionnaire internal consistency was estimated by Cron-
bach’s alpha17. 
Sample size was based on pre-test with 80 patients, as-
suming alpha and beta errors of 5% and 20%, respectively, 
and results were tabulated in MSExcel 2003 and analyzed 
by SPSS 17.0 soware19. Two-sided p-value of < 0.05 was 
considered statically significant17. 
RESULTS
One hundred patients with UC were interviewed. The main 
demographic and quality of life data are shown in Table 2.
It is noteworthy that there was a female predominance 
(6:1), involvement of working-age adults, mean total 
DLQI score classified as “severe impairment of quality of 
life”, and high frequency of angioedema. 
There was no exclusion of patients, and all agreed to 
participate.
Cronbach’s alpha resulted in 0.73, ensuring internal 
consistency of the questionnaire.
Scores of the di±erent domains assessed by the DLQI 
questionnaire are shown in Figure  1. Analysis of scores 
(hierarchical clustering) and residual analysis of the con-
tingency table showed more severe involvement of CU in 
areas relating to symptoms and feelings (questions 1 and 
2), daily activities (question 3) and leisure (question 5).
Presence of angioedema was the only variable that was 
significantly associated with worst scores on DLQI, even 
when adjusted for gender, age, disease duration and edu-
cation. The mean score (± SD) of DLQI for patients with 
angioedema was 14.3 (± 5.3) versus 9.9 (± 3.8) for patients 
without angioedema (p < 0.01).
Regarding gender, there was a greater impact of CU on 
quality of life of women in question 4 (clothing), while in 
question 7 (work/study) and question 10 (treatment), the 
impact was greater for men (p < 0.05).
Patients with more education (secondary and higher 
education) reported higher impact of CU on quality of 
life on questions 2 (embarrassment) and 6 (sports), when 
compared with those without education or with primary 
education (p < 0.05). Older ages were significantly associ-
ated with lower scores only on question 4 (clothing).
Finally, longer duration of illness was associated with 
lower scores on questions 1 (symptoms) and 4 (clothing), 
but with higher scores on questions 2 (embarrassment) 
and 7 (work/study) (p < 0.05).
DISCUSSION
In this study of Brazilian adult patients, CU has caused 
severe impairment of quality of life, particularly among 
patients with CU and angioedema (DLQI 14.3  points) 
compared with patients with CU alone (DLQI 9.9 points).
Angioedema is o±en associated with long-lasting and 
resistant cases of CU, as occurs in patients with physical 
urticaria; positive autologous serum test; and more exten-
sive cases7,20,21.
In addition, patients with angioedema su±er major 
limitations related to di±erent daily activities, especially 
due to the symptoms that cause embarrassment in public 
places, sports, work/study, and leisure.
The authors believe that the high frequency of angio-
edema in this series occurred because the institution is a 
referral service, which receives cases that  are more severe, 
long-lasting, and less responsive to treatment with conven-
tional antihistamines22.
Variables Data 95% CI
Sex (n)    
Female 86 79.1%-92.9%
Male 14 7.1%-20.9%
Age (years) – mean (SD) 41.8 (14.5) 38.9%-44.7%
Age at onset 36.1 (14.0) 33.3%-38.9%
Disease duration 5.7 (4.6) 4.8%-6.6%
Education (n)    
Illiterate 5 0.7%-9.3%
Elementary school 57 47.2%-66.8%
High school 34 24.6%-43.4%
Higher education 4 0.1%-7.9%
Angioedema (n) 82 74.4%-89.6%
DLQI total – mean (SD) 13.5 (5.3) 12.4%-14.5%
DLQI, Dermatology Life Quality Index; SD, standard deviation; 95% CI, 95% confidence interval.
Table 2 – Demographic variables and patients’ quality of life
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National studies of other dermatoses, also chronic, 
such as Hansen’s disease and psoriasis, atopic dermati-
tis, and vitiligo, among others (Table 3), also observed a 
substantial impact on QoL of their patients, indicated by 
the high scores on DLQI7,16,23-26. However, in this work, we 
found mean scores even higher for patients with CU.
In fact, the CU has an impact on QoL, and its indi-
ces resemble those of patients aer myocardial infarc-
tion7,20,21,27. Although chronic, CU has features of acute and 
unusual onset. Such unpredictability can limit everyday 
activities and generate sudden limitations.
Another factor that may contribute to the perception 
of QoL impairment refers to the high coexistence of psy-
chiatric disorder (35-50%), especially anxiety, depression, 
somatoform disorders, and sleep disorders, as identified in 
other studies involving series of patients with CU28-30.
We also found strong association of female with CU; 
this finding is consistent with other previous studies6,7,22. In 
fact, women are more aected not only by CU, but by other 
autoimmune diseases.
Similarly, the perceived impact on the QoL of women 
was dierent from men in domains related to clothing, 
work/study, and treatment. A possible explanation for this 
is the characteristic of female vanity that may have inu-
enced the higher scores for daily activities. Jobs requiring 
concentration, such as drivers and machine operators, are 
predominantly male, which may explain the higher scores 
of men in these domains, mainly inuenced by the side 
eects of treatments.
The impact on clothing was also significantly higher 
among young people, probably due to the more meaning-
ful representation of clothing in their everyday lives. 
The educational level was associated with greater im-
pact on questions relating to symptoms and feelings, as 
well as leisure, suggesting that patients with more educa-
tion are more socially exposed or overconcerned with such 
exposure.
Patients with long-lasting disease complain less about 
the impact related to symptoms and clothing, however, 
they reported greater social embarrassment and impact 
on work. 
Disease Mean DLQI
Chronic urticaria 13.5
Hansen’s disease 11.0
Psoriasis 10.3
Basal cell carcinoma 8.5
Atopic dermatitis 7.9
Acne 7.4
Contact dermatitis 6.5
Alopecia areata 4.6
Vitiligo 4.0
DLQI, Dermatology Life Quality Index.
Table 3 – DLQI mean scores for dermatological conditions 
in Brazilian populations16,26
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Figure 1 – Frequency of the questionnaire Dermatology Life Quality Index (DLQI) answers according to the question evaluated.
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Resignation in the face of chronic disease can result 
from strong doctor-patient relationship and realistic un-
derstanding of disease severity, minimizing their fears. On 
the other hand, the chronicity of disease can lead to events 
of absenteeism, professional rehabilitation, and frustra-
tions in social relations.
Possible limitations of this study may be the lack of 
comparative analysis with other dermatoses and the ho-
mogeneity of patients coming from a tertiary public ser-
vice, restricting data generalization, mainly related to 
socioeconomic characteristics and severity of clinical 
conditions. However, qualitative studies are, per se, popu-
lation perceptions linked to cultural aspects that should 
not be compared between groups, but that characterize a 
population.
CONCLUSION
Chronic urticaria seriously compromises the quality of life 
of patients evaluated at a university service in Brazil, par-
ticularly of patients with angioedema.
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